Open for inclusion

Full dose monotherapy S-1 (followed by irinotecan) compared to reduced dose combination therapy (S-1/pxaliplatin followed by S-1/irinotecan) as initilal therapy for older patients with metastatic colorectal cancer

Cancer type: Colorectal cancer

Phase: II

Principal Investigator: Österlund Pia

Country: FI

Keywords: Finland, Helsinki

Status: Open for inclusion